2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
CNS
1
Conditions
Sexual Infantilism
1
Pancreatic Neoplasms
1
Craniopharyngioma
1
Interventions
pembrolizumab
1265
Specimen Handling
926
Magnetic Resonance Spectroscopy
830
Carboplatin
823
Cyclophosphamide
800
Cisplatin
723
Nivolumab
669
Paclitaxel
627
Radiotherapy
611
Gemcitabine
573
Biopsy
557
Bevacizumab
478
Dexamethasone
438
fludarabine
407
Docetaxel
380
venetoclax
368
Oxaliplatin
364
Capecitabine
358
Fluorouracil
355
atezolizumab
350
durvalumab
332
Rituximab
330
Drug Therapy
326
Doxorubicin
316
Radiosurgery
315
Standard of Care
309
Blood Specimen Collection
308
Pemetrexed
305
Ipilimumab
299
Radiation
286
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Exenatide
×
1 year
×
Clear all
NCT05663515
2026-06-02
EXCEED
AstraZeneca
Recruiting
24,000 enrolled
NCT02860923
2026-05-22
CRANIOEXE
University Hospital, Bordeaux
Phase 3
Completed
42 enrolled